Evidence Trace, complete trial record

In plain terms

In plain terms: Panax Ginseng shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.

Panax Ginseng

C Limited: small, mixed or unreplicated trials

Category Supplements

Evidence Cochrane review of small randomized trials; trivial effect at low to moderate certainty

Reviewed July 2026

PMIDs 33871063 · 41696741 · 12394711

The endpoint this grade is based on: self_report, Erectile function in mild to moderate erectile dysfunction, on Korean red ginseng or ginseng berry extract at about 600 to 2,700 mg/day for 4 to 12 weeks: the Cochrane review found a statistically significant but trivial gain on erectile function scales, below the minimal clinically important difference, at low to moderate certainty, and more men reporting the ability to have intercourse at low certainty. No other use carries a letter.

The evidence as the record states it

Evidence record

PMID 33871063 PMID 41696741 PMID 12394711

Lee et al. (Cochrane Database of Systematic Reviews, 2021; PMID 33871063): 9 placebo-controlled trials, 587 men aged 20 to 70 with mild to moderate erectile dysfunction, up to 12 weeks; IIEF erectile function domain 3.52 points higher (minimal important difference 4, low certainty) and IIEF-5 2.39 points higher (minimal important difference 5, moderate certainty), which the authors call a trivial effect; self-reported ability to have intercourse more likely (risk ratio 2.55, low certainty); little to no difference in adverse events (low certainty). Hong et al. (J Urol, 2002; PMID 12394711): double-blind crossover, 45 men, Korean red ginseng 900 mg three times daily for 8 weeks; IIEF scores and penile tip rigidity better than placebo. Ho et al. (J Tradit Complement Med, 2026; PMID 41696741): meta-analysis of 14 trials of herbal supplements for erectile dysfunction, 1,227 men; ginseng improved erectile function, pooled with other herbs. Grade C: small, short, mostly single-region trials with a trivial effect on a self-reported scale.

PMID 33871063 PMID 41696741 PMID 12394711

Evidence by specific use

Erectile function in mild to moderate erectile dysfunction, Korean red ginseng

Grade C

Lee et al. (Cochrane, 2021; PMID 33871063): 9 small placebo-controlled trials; erectile function scores higher than placebo by amounts below the minimal clinically important difference, which the review calls trivial, at low to moderate certainty; self-reported ability to have intercourse improved at low certainty. Hong et al. (2002; PMID 12394711): 45 men, 900 mg three times daily, crossover, positive. Ho et al. (2026; PMID 41696741): herbal-supplement meta-analysis, ginseng positive, pooled with other herbs. Small, low-certainty positive trials on a self-reported scale: C, and the self-report ceiling is B in any case.

PMID 33871063 PMID 12394711 PMID 41696741

Why Grade C and not Grade B

Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.

What would move this grade

A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.

How to track whether this is working For the graded use, the IIEF erectile function domain at baseline and 8 to 12 weeks, the scale the trials used, remembering that the pooled gain sat below the 4-point difference patients notice. Fatigue, immune and cognitive applications carry no letter on this record. Ginsenoside content varies widely; the trials used Korean red ginseng or a standardized berry extract.